EGFR and neoplasm: Li et al. [30] found that EGFR-TKI treatment of tumor-tissue EGFR M+ patients prolonged the PFS of plasma EGFR M- patients compared with plasma EGFR M+ patients, though the result was not statistically significant (19.7 months vs. 11.0 months, P = 0.102).